Respiratory Oxygen Adherence Monitor for Chronic Obstructive Pulmonary Disease Patients

Launched by BARRON ASSOCIATES, INC. · Mar 7, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a device called "ROAM" designed for patients with chronic obstructive pulmonary disease (COPD) who use oxygen therapy at home. The main goal is to see if feedback from the ROAM device can help patients stick to their oxygen therapy better over a period of five weeks. Participants will be divided into two groups: one will receive information about their oxygen use and another will not. The researchers want to find out if having this feedback improves how often patients use their oxygen as prescribed.

To be eligible for the trial, participants should be adults aged 70 and older who have a diagnosis of COPD and are using continuous oxygen therapy at home. They should not have had any recent health issues, like hospitalizations or respiratory infections, in the past six weeks. During the study, participants will use their oxygen as usual while wearing the ROAM device and will visit the clinic twice to complete some questionnaires about their experience. This trial is not yet recruiting, but it aims to help improve oxygen therapy adherence for COPD patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Post-Bronchodilator FEV1/FVC\<.80
• • Participants with medical history of COPD
• • Prescription for oxygen use via nasal cannula or mask at home
• • At baseline of health with no hospitalization/exacerbation within the past 6 weeks
• • Use of Continuous oxygen at baseline
• Exclusion Criteria:
• • Post -Bronchodilator FEV1/FVC ≤25%
• • Intermittent oxygen use at home
• • Inability to understand simple instructions
• • Respiratory exacerbation or infections within 6 weeks prior to screen visit
• • Not at baseline of medical health prior to screen visit